echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > As a first-line COVID-19 treatment, a simple nasal antibody spray has "great potential"

    As a first-line COVID-19 treatment, a simple nasal antibody spray has "great potential"

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A unique tiny antibody produced by the llama can be used as a simple nasal spray to provide patients with a new first-line treatment for Covid-19


    Research led by scientists at the Rosalind Franklin Institute has shown that nanobodies—a smaller and simpler form of antibodies produced by llamas and camels—can effectively target the disease that causes Covid-19.


    They found that the short chain of this molecule can be produced in large quantities in the laboratory, and when injected into an infected animal model, it significantly reduces the signs of Covid-19 disease


    Nanobodies are tightly bound to the SARS-CoV-2 virus, and neutralizing it in cell culture can provide a cheaper and easier-to-use alternative to human antibodies extracted from patients recovered from Covid-19


    The Department of Public Health of the United Kingdom called the study "huge potential in the prevention and treatment of Covid-19," adding that the nanobody "is one of the most effective SARS-CoV-2 neutralizers we have tested


    "Nanobodies have many advantages over human antibodies," said Professor Ray Owens, head of protein production at the Rosalind Franklin Institute and lead author of the study


    The research team's findings, published in " Nature Communication on" magazine


    The spike protein is located on the outside of the virus and is responsible for binding to human cells and infecting them


    Although the injection did not make Feifei sick, it triggered her immune system to fight it by producing nano-antibodies against viral proteins


    These Nanobodies are then combined into three chains to enhance their ability to bind to viruses


    The team discovered that the three Nanobody chains can neutralize the original variant of the Covid-19 virus and the alpha variant first discovered in Kent, UK


    When one of the nanobody chains-also known as the trimer-was injected into hamsters infected with SARS-CoV-2, the disease of these animals was significantly reduced, and the weight loss after 7 days was much lower than that of no treatment Hamster


    Professor James Naismith, director of the Rosalind Franklin Institute, helped lead the study.


    These results are the first step in the development of a new treatment for Covid-19, which may prove invaluable as the pandemic continues


    "Although the vaccine has proven to be very successful, not everyone responds to the vaccine, and the individual's immunity weakens at different times," said Professor Naismith


    Professor Naismith added that if successful and approved, Nanobodies will provide an important treatment worldwide because they are easier to produce than human antibodies and do not need to be stored in cold storage facilities


    The research team includes scientists from the University of Liverpool, the University of Oxford and the Department of Public Health England, and now hopes to obtain funding to conduct further research in preparation for human clinical research
    .

    Professor Miles Carroll, Deputy Director of the National Infection Service (PHE) of Public Health England, said: "Although this research is still in its early stages, it opens up significant possibilities for the use of effective nanobodies to treat COVID-19
    .

    "These are the most effective SARS-CoV-2 neutralizers
    we have tested in the public health department .
    We believe that the unique structure and strength of nanobodies contribute to their great potential in preventing and treating COVID-19.
    We Looking forward to cooperating to advance this work into clinical research
    .
    "

    Dr Andrew Byrne, Director of EPSRC Partnerships said:

    "Using the unique properties of llama nanobodies, this research may lead to an important new form of Covid-19 treatment that is cheaper to produce and easier to use
    .

    "This vividly illustrates the possible impact of the long-term discovery research carried out by the Rosalind Franklin Institute at the forefront of physics and life sciences
    .
    "

    Co-author, Professor James Stewart, Professor of Molecular Virology at the University of Liverpool, said: “Preclinical trials of nanobodies in hamsters are very encouraging and show that they may be effective in treating COVID-19 and help prevent infection
    .
    Such treatments will be very important for people who are vaccinated or who are not suitable or ineffective
    .
    "

    Professor Owens said: "When a new virus emerges in the future, the universal technology we develop can respond to it, which is very important to produce new treatments as soon as possible
    .
    "

    Reference: A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19.
    22 September 2021, Nature Communications .

    DOI: 10.
    1038/s41467-021-25480-z

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.